Diridavumab, the alternative names CR6261, is a human monoclonal antibody direct against influenza A hemagglutinin. The CR6261 antibody was first discovered by the Scripps Institute and Crucell, a dutch biopharmaceutical company, and later developed by Janssen Pharmaceutical Companies of Johnson & Johnson under the trade name diridavumab. Cr6261 is under investigation in clinical trial NCT02016066 (A Study to Assess the Safety, Pharmacokinetics and Immunogenicity of Diridavumab in Japanese Healthy Participants).icon
Research Grade Diridavumab Biosimilar
Protein A or G purified from cell culture supernatant.
Please contact with the lab for this information.
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.
CR-6261, CR6261, CAS: 1393659-46-5, Influenza Virus (Flu)
For research use only .Not suitable for clinical or therapeutic use.